Screener
ImmunityBio, Inc. IBRX Reportable Segment — Research and Development Expense, Internal
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept ibrx:ResearchAndDevelopmentExpenseInternal.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Personnel-related costs | 25,850 | 23,065 |
| Equipment, depreciation, and facility costs | 13,588 | 13,192 |
| Other research and development costs | 8,469 | 6,466 |
| Total internal research and development expense | 47,907 | 42,723 |
| Total research and development expense (including amounts with related parties) | 67,989 | 48,234 |
| Selling, general and administrative (including amounts with related parties) | 45,770 | 32,654 |
| Total operating expenses | 113,759 | 80,888 |
| Loss from operations | (69,791) | (64,429) |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s reportable segment — research and development expense, internal?
- ImmunityBio, Inc. (IBRX) reported reportable segment — research and development expense, internal of $47.91M in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — research and development expense, internal changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — research and development expense, internal increased by 12.1% year-over-year, from $42.72M to $47.91M.
- What is the long-term trend for ImmunityBio, Inc.'s reportable segment — research and development expense, internal?
- Over 2 years (2023 to 2025), ImmunityBio, Inc.'s reportable segment — research and development expense, internal has grown at a 7.0% compound annual growth rate (CAGR), from $165.24M to $189.29M.
- What does reportable segment — research and development expense, internal mean?
- Reflects the costs incurred for R&D activities performed in-house by the company's own staff and facilities. This highlights the company's commitment to maintaining proprietary research capabilities.
Ask your AI about ImmunityBio, Inc.'s reportable segment — research and development expense, internal.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude